Want to see BDTX full AI Analyst Report?
BDTX Stock Chart & Stats
$3.06
-$0.07(-3.30%)
At close: 4:00 PM EST
$3.06
-$0.07(-3.30%)
Day’s Range― - ―
52-Week Range$1.60 - $4.94
Previous CloseN/A
Volume170.82K
Average Volume (3M)2.16M
Market Cap
$108.87M
Enterprise Value$83.50M
Total Cash (Recent Filing)$118.26M
Total Debt (Recent Filing)$17.88M
Price to Earnings (P/E)―
Beta2.35
Next Earnings
Aug 06, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding57,301,773
10 Day Avg. Volume2,604,100
30 Day Avg. Volume2,164,581
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.23
Price to Sales (P/S)1.97
P/FCF Ratio4.67
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-738.98
Enterprise Value/Ebitda-2.19
Forecast
1Y Price Target
$11.00Price Target Upside259.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.65
Revenue Forecast (FY)$7.14M
Bulls Say, Bears Say
Bulls Say
Precision Mutation-targeting PlatformA proprietary mutation-targeting platform provides durable strategic differentiation: it enables identification of genetically defined patient subsets, increases likelihood of targeted clinical success, and supports partnership and licensing models that can persistently enhance pipeline value independent of short-term market moves.
Positive Phase 2 Silevertinib DataRobust, durable Phase 2 efficacy and strong CNS activity in non-classical EGFR NSCLC materially de-risks the lead program. These results support a clearer regulatory/pivotal path, strengthen partner interest and future commercial potential, and represent a lasting clinical validation for development plans.
Manageable LeverageLow absolute debt and a modest debt-to-equity ratio provide financial flexibility typical for biotech: this reduces near-term refinancing pressure, helps preserve optionality for R&D funding or partnerships, and makes balance-sheet-driven solvency less likely to constrain operations over the medium term.
Bears Say
Weak Cash GenerationSustained negative operating and free cash flow creates runway and execution risk: ongoing cash burn forces reliance on financing or partnerships, can delay programs if funding gaps appear, and may necessitate dilutive raises or deal concessions that affect long-term shareholder value.
TTM Revenue $0 And Return To LossesVolatile and currently absent revenue undermines predictability: the company cannot rely on recurring product sales to fund operations, making budgeting and multi-year planning dependent on one-off events or milestones and increasing execution risk if clinical timelines slip.
Dependence On Collaboration RevenueReliance on partnerships and milestone payments concentrates revenue risk: without marketed products, cash inflows are uneven and contingent on third-party deal terms and development success, which elevates medium-term funding uncertainty and strategic vulnerability to partner actions.
Black Diamond Therapeutics News
BDTX FAQ
What was Black Diamond Therapeutics, Inc.’s price range in the past 12 months?
Black Diamond Therapeutics, Inc. lowest stock price was $1.60 and its highest was $4.94 in the past 12 months.
What is Black Diamond Therapeutics, Inc.’s market cap?
Black Diamond Therapeutics, Inc.’s market cap is $108.87M.
When is Black Diamond Therapeutics, Inc.’s upcoming earnings report date?
Black Diamond Therapeutics, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 28 days.
How were Black Diamond Therapeutics, Inc.’s earnings last quarter?
Black Diamond Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.184 by $0.024.
Is Black Diamond Therapeutics, Inc. overvalued?
According to Wall Street analysts Black Diamond Therapeutics, Inc.’s price is currently Undervalued.
Does Black Diamond Therapeutics, Inc. pay dividends?
Black Diamond Therapeutics, Inc. does not currently pay dividends.
What is Black Diamond Therapeutics, Inc.’s EPS estimate?
Black Diamond Therapeutics, Inc.’s EPS estimate is -0.2.
How many shares outstanding does Black Diamond Therapeutics, Inc. have?
Black Diamond Therapeutics, Inc. has 57,301,773 shares outstanding.
What happened to Black Diamond Therapeutics, Inc.’s price movement after its last earnings report?
Black Diamond Therapeutics, Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.184. Following the earnings report the stock price went down -3.546%.
Which hedge fund is a major shareholder of Black Diamond Therapeutics, Inc.?
Currently, no hedge funds are holding shares in BDTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Black Diamond Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.00 (259.48% Upside)
$11.00 (259.48% Upside)
Blogger Sentiment
Bullish
BDTX Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 101.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.80%
12-Months-Change
Fundamentals
Return on Equity
-36.37%
Trailing 12-Months
Asset Growth
-24.58%
Trailing 12-Months
Company Description
Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor. This compound is engineered to neutralize oncogenic proteins driven by non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) driver mutations. The firm is also progressing BDTX-1535, a brain-penetrant inhibitor addressing a range of EGFR mutations, including conventional, inherent resistance, and acquired resistance forms. Concurrently, it is advancing BDTX-4933, another brain-penetrant inhibitor targeting oncogenic BRAF alterations across Class I, II, and III categories. Black Diamond maintains a strategic alliance with OpenEye Scientific Software, Inc. Established in 2014, the company was initially known as ASET Therapeutics, Inc. before adopting its current name, Black Diamond Therapeutics, Inc., in January 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
BDTX Stock 12 Month Forecast
Average Price Target
$11.00
▲(259.48% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Galectin Therapeutics
―
Voyager Therapeutics
―
Diamedica Therapeutics
―
Instil Bio
―
Ownership Overview
9.06% Insiders
17.25% Mutual Funds
34.13% Other Institutional Investors
28.73% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---